CLASSIC CONGENITAL ADRENAL HYPERPLASIA
Clinical trials for CLASSIC CONGENITAL ADRENAL HYPERPLASIA explained in plain language.
Never miss a new study
Get alerted when new CLASSIC CONGENITAL ADRENAL HYPERPLASIA trials appear
Sign up with your email to follow new studies for CLASSIC CONGENITAL ADRENAL HYPERPLASIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill shows promise for rare hormone disorder in Long-Term trial
Disease control Recruiting nowThis study is testing the long-term safety and effectiveness of a daily pill called atumelnant for people with classic congenital adrenal hyperplasia (CAH). The drug works by blocking a hormone receptor to help control excess androgen production. Researchers will monitor 150 part…
Matched conditions: CLASSIC CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill could help kids with rare hormone disorder cut back on steroids
Disease control Recruiting nowThis study tests a daily oral medication called atumelnant in children aged 1 to 18 with classic congenital adrenal hyperplasia, a genetic condition that disrupts hormone production. The goal is to see if the drug can safely normalize hormone levels and allow patients to lower th…
Matched conditions: CLASSIC CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE2, PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New pill may help adults with rare adrenal disorder cut back on steroids
Disease control Recruiting nowThis study tests a new drug, atumelnant, in 150 adults with classic congenital adrenal hyperplasia (CAH). The goal is to see if it can safely control hormone levels and allow patients to take lower doses of their usual steroid medications. Participants will receive either atumeln…
Matched conditions: CLASSIC CONGENITAL ADRENAL HYPERPLASIA
Phase: PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC